Centro De Oftalmologia Barraquer S.A.

Barcelona 19 trials 7 recruiting

19 Registered trials

7 Currently recruiting

Organisation

Centro De Oftalmologia Barraquer S.A.

Location

Barcelona, Spain

Identifier

ORG-100044024

Address

Calle Muntaner 314, 08021, Spain

Departments

724011: Oftalmología
Centro de Oftalmologia Barraquer
NA
Oftalmología
Oftalmology
Ophtalmology
Ophthalmogoly
Ophthalmology

Clinical trials at this site (19)

Search interface

Study to Assess the Ability of ONL1204 to Slow the Progression of Atrophic Age-related Macular Degeneration Recruiting

2024-513174-22-00 Atrophic Age-related Macular Degeneration (AMD) 4 2026-04-14
EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPER-REFLECTIVE MATERIAL Recruiting

2025-522701-38-00 SUBRETINAL HYPERREFLECTIVE MATERIAL 6 2026-02-26
Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting

2024-512298-28-00 Neovascular age-related macular degeneration 11 2025-12-18
A phase IV, multicentre, open-label, single-arm study to investigate the efficacy, safety and durability of faricimab (RO6867461) in caucasi… Recruiting

2024-515640-22-00 polypoidal choroidal vasculopathy 6 2025-08-06
A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge… Recruiting

2023-509547-27-00 Geographic Atrophy Secondary to Age-Related Macular Deg 5 2025-05-22
A clinical trial to evaluate the safety and the efficacy of NEXAGON ® (Lufepirsen Ophthalmic Gel) in subjects with Persistent Corneal Epithe… Recruiting

2023-507030-24-00 Persistent Corneal Epithelial Defects 4 2025-04-30
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting

2022-500747-21-00 Geographic Atrophy 4 2025-02-27
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended

2025-520809-12-00 Diabetic Macular Edema 10 2025-10-16
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema… Ended

2024-510944-30-00 Diabetic Macular Edema 10 2024-11-22
ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Sub… Ended

2024-511482-11-00 Dry Age-Related Macular Degeneration (Dry AMD) 5 2024-11-20
A phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine… Ended

2024-516315-24-00 myopia 5 2022-05-27
A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended

2023-507131-38-00 Neovascular Age-Related Macular Degeneration (nAMD) 5 2022-05-16
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended

2023-507130-24-00 Neovascular age-related macular degeneration (nAMD) 5 2021-10-22
A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended

2023-507217-10-00 Thyroid eye disease 5 2024-04-12
SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of… Ended

2022-502697-16-00 Neurotrophic Keratopathy 5 2023-08-29
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended

2022-500746-16-00 Geographic Atrophy 4 2023-08-11
An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended

2024-515185-13-00 geographic atrophy 5 2022-12-21
Evaluation of the efficacy and safety of topical treatment on clinical signs and symptoms of dry eye disease associated with moderate meibom… Ended

2024-518093-13-00 Dry Eye and Meibomian Gland Dysfunction 6 2021-10-26
A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended

2024-512879-13-00 Neovascular age-related macular degeneration (wet AMD) 5 2021-09-23